METHODS OF TREATING CANCER WITH AN ANTI-PD-L1 ANTIBODY
Application
US20260078187A1
Kind: A1
Mar 19, 2026
Inventors
Daniel ShinYu CHEN, Cathleen AHEARN, Alan Bart SANDLER
Abstract
The present disclosure relates to methods, uses, and kits related to treating cancers by administering an anti-PD-L1 antibody (e.g., atezolizumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered in 840 mg every 2 weeks or 1680 mg every 4 weeks for two or more cycles.
CPC Classifications
C07K 16/2827
A61K 31/282
A61K 31/337
A61K 31/7048
A61K 39/3955
A61P 35/00
A61K 2039/505
A61K 2039/54
A61K 2039/545
C07K 2317/56
Filing Date
2025-09-04
Application No.
19319392